9 Meters Biopharma, Inc. (NMTR): Price and Financial Metrics
NMTR Price/Volume Stats
| Current price | $0.07 | 52-week high | $6.56 |
| Prev. close | $0.13 | 52-week low | $0.07 |
| Day low | $0.07 | Volume | 9,957,800 |
| Day high | $0.11 | Avg. volume | 315,915 |
| 50-day MA | $0.64 | Dividend yield | N/A |
| 200-day MA | $1.54 | Market Cap | 1.04M |
NMTR Stock Price Chart Interactive Chart >
9 Meters Biopharma, Inc. (NMTR) Company Bio
9 Meters Biopharma, Inc. operates as a biotechnological company. The Company focuses on development of drugs and treatments for rare disorders and unmet needs. 9 Meters Biopharma serves customers worldwide.
Latest NMTR News From Around the Web
Below are the latest news stories about 9 METERS BIOPHARMA INC that investors may wish to consider to help them evaluate NMTR as an investment opportunity.
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately. |
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 20239 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. |
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. |
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 20229 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022. |
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock |
NMTR Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -93.27% |
| 3-year | -99.70% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -93.56% |
| 2021 | 13.93% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...